The Accreditation Council for Medical Affairs (ACMA) announced that it will launch a new Board Certification program focused on biologics and biosimilars in November 2022. The Board Certified Biologics and Biosimilars Specialist (BCBBS) program will be for healthcare professionals (e.g., pharmacists, prescribers, PhDs, Industry/MSLs etc.) with the goal of creating a new industry standard for effective management of biologics.
Read more about the new program here.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.